KALA BIO, Inc. (NASDAQ:KALA) Short Interest Update

KALA BIO, Inc. (NASDAQ:KALA) was the target of a significant decrease in short interest in November. As of November 15th, there was short interest totalling 30,500 shares, a decrease of 18.7% from the October 31st total of 37,500 shares. Currently, 0.8% of the shares of the stock are short sold. Based on an average daily volume of 21,400 shares, the short-interest ratio is presently 1.4 days.

KALA BIO Stock Down 2.0 %

Shares of NASDAQ KALA traded down $0.14 during mid-day trading on Monday, hitting $6.72. The company had a trading volume of 2,710 shares, compared to its average volume of 81,772. The company has a market capitalization of $30.98 million, a PE ratio of -0.54 and a beta of -2.13. The business’s 50-day simple moving average is $6.17 and its 200 day simple moving average is $6.26. The company has a debt-to-equity ratio of 3.18, a current ratio of 2.15 and a quick ratio of 2.15. KALA BIO has a 1-year low of $4.21 and a 1-year high of $10.97.

KALA BIO (NASDAQ:KALA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.43) by $0.50. On average, analysts predict that KALA BIO will post -10.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on KALA shares. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of KALA BIO in a report on Friday, November 15th. Oppenheimer restated an “outperform” rating and set a $15.00 price target on shares of KALA BIO in a research note on Monday, August 19th.

Hedge Funds Weigh In On KALA BIO

A hedge fund recently bought a new stake in KALA BIO stock. SR One Capital Management LP acquired a new position in shares of KALA BIO, Inc. (NASDAQ:KALA) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO makes up approximately 1.0% of SR One Capital Management LP’s investment portfolio, making the stock its 9th largest position. SR One Capital Management LP owned about 15.76% of KALA BIO as of its most recent SEC filing. 24.61% of the stock is currently owned by institutional investors and hedge funds.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.